ERISA Ledger · U.S. DOL EBSA Form 5500 (2024)

Alnylam Pharmaceuticals, INC.

Official 2024 U.S. DOL Form 5500 summary for Alnylam Pharmaceuticals, INC. (Alnylam Pharmaceuticals, INC. Savings & Investment Plan · EIN 04-3696884 · PN 001): $344.00M net assets, 1,815 active participants, and $11.68 per $10,000 (11.68 bps).

Reported Form 5500 Fee & Service Summary

Plan SponsorAlnylam Pharmaceuticals, INC.
Filing IdentifierAlnylam Pharmaceuticals, INC. Savings & Investment Plan · EIN 04-3696884 · PN 001
Plan Category & State401(k) Defined Contribution (MA)
Asset-Size Peer Cohort$100M-$500M
Plan Net Assets (2024)$344.00M
Active Participants1,815
Direct Admin Fee Rate$11.68 per $10,000 (11.68 bps)
Cohort Peer Median$9.75 per $10,000 (9.75 bps)
Primary Recordkeeper / ProviderFidelity Investments
Schedule H Line 4a RemittanceTimely Employer Remittance (0 reported on Line 4a)

Browse all 78,373 plans & Schedule C vendors · Methodology · Meru AI

Cross-Agency Entity Graph

Related Filings Across Meru Platforms

Verified federal filings reconciled for Alnylam Pharmaceuticals across sibling Meru AI platforms.